Lyophilization Capabilities

Press Release – Gipharma Srl
Lyophilization Capabilities

GIPharma logo

Contact Supplier: Gipharma Srl
Supplier Press Release: Lyophilization Capabilities
Address: Strada Crescentino, 13040 Saluggia (Vc), Italy
Tel: +39 0161 487 141
Fax: +39 0161 487 140
Website: www.gipharma.com

OCTOBER 02, 2012

Lyophilization Capabilities

Gipharma is pleased to announce its enhanced lyophilization capabilities, the completion of its new sterile injectables production line which is now fully operational.

With Gipharmas’ doubled production capacity and long standing experience, they are able to offer a wide range of CMO services:

• Production of small volume lyophilized and sterile liquids in vials
• By aseptic manufacturing and terminal sterilization
• For commercial and clinical trials batches
• Technical Transfer and ICH Methods Validation
• Finished products and raw materials testing
• Microbiological testing
• Batch release for Europe
• ICH Stability Studies

Gipharma will be attending CPhI Worldwide and its co-located event ICSE in Madrid from 9 – 11 October exhibiting at stand 10C39.

If you are looking for additional capacity for your lyophilized products or to find out more about the array of CMO services, Gipharma welcomes you to visit their stand where the team will be delighted to show you in more detail their capabilities and to discuss future business opportunities.

About Gipharma Srl
Gipharma is a young growing pharmaceutical contract manufacturer for small volume injectable and freeze dried solutions, by aseptic as well as terminally sterilized processes, based in North West Italy. Gipharma specializes in oxygen sensitive products such as radiopharmaceutical cold kits for which it has a long standing experience and supplies all leading Imaging players in Europe.

Press Contact:
Giorgio Chieregatti
Gipharma Srl
Strada Crescentino, 13040 Saluggia (Vc), Italy
Mobile: +39 335 1436 836
E-mail: info@gipharma.com
www.gipharma.com

For more information or to discuss lyophilization capabilities please contact us directly.

Comments are closed.